



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q78382

SHICHIJO, Shigeki

Appln. No.: 10/734,049

Group Art Unit: Unknown

Confirmation No.: Unknown

Examiner: Not Yet Assigned

Filed: December 12, 2003

For: TUMOR ANTIGEN

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents, other than any U.S. patents and patent publications, is submitted herewith.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/734,049

The NCBI Sequences are highly homologous to sequences of the present application.

The SEREX database sequences are identical or partially homologous to sequences of the present application as follows:

IDENTICAL

SEREX

ID 456 SEQ ID NO. 214- SEQ ID 289

ID 629 SEQ ID NO. 228

ID 1226 SEQ ID 269

ID 163 SEQ ID 261-SEQ ID NO. 332

ID 116 SEQ ID 236

ID 1197 SEQ 299

PARTIALLY HOMOLOGOUS

SEREX

ID 1072 SEQ ID NO. 307

ID 1233 SEQ ID NO. 343

ID 979 SEQ ID NO. 342


ID 567 SEQ ID NO. 324

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: 10/734,049

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account. A duplicate copy of this paper is attached.

Respectfully submitted,


Louis Gubinsky
Registration No. 24,835

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: February 26, 2004